Medical, Industry Outlook

Are Nitrosamines aConcern for BiologicManufacturers?

July 12, 2023

Are Nitrosamines a Concern
The discovery of nitrosamine genotoxins in several
pharmaceuticals has led to monitoring and re-evaluation of
manufacturing practices for those products considered atrisk. This article provides an assessment of nitrosamine
contamination specifically in biologics and contrasts the
potential risks between these product types.

Spotlight

Orphazyme

Orphazyme is a Danish biotech-company focused on the development of novel therapies for lysosomal storage diseases. Orphazyme was founded in June 2009 by Thomas Kirkegaard Jensen (PhD, CEO), Martin Rahbek Kornum (Patent Attorney, Ch. of Board), Anders Hinsby (Partner, Bankinvest Biomedical Venture) & Marja Jäättelä (Prof., Head of Dep. of Apoptosis) via a pre-seed grant from the Novo Nordisk Foundation.

OTHER WHITEPAPERS
news image

Automated Extraction of High Molecular Weight DNA

whitePaper | November 14, 2019

SmartExtraction significantly simplifies the entire automated workflow of DNA extraction, setting new standards with regard to efficiency, yield and quality of the DNA.

Read More
news image

Long-term follow-up studies of cell and gene therapies

whitePaper | September 29, 2022

The market is experiencing a surge in the availability of cell and gene therapies (CGTs); it’s estimated that by 2025 as many as 20 will be introduced into the US each year.1,2

Read More
news image

Connecting materials sciences with fungal biology: a sea of possibilities

whitePaper | March 1, 2022

The Special Issue “Connecting materials science with fungal biology” celebrates recent breakthroughs in the fabrication of fungal-based materials, all of which have been made possible by the interdisciplinary and transdisciplinary collaboration of fungal biologists and biotechnologists with artists, designers, materials scientists, and architects

Read More
news image

Internal Co-ordination Group for Biotechnology

whitePaper | October 19, 2022

The Organisation for Economic Co-operation and Development and its member countries have been addressing issues related to biotechnology since 1982.

Read More
news image

Understanding Single-Pass Tangential Flow Filtration and the New Era of Bioprocessing

whitePaper | December 22, 2022

Single-pass tangential flow filtration (SPTFF) technology from Pall Corporation is revolutionizing current and future bioprocessing platforms with its implementations in biotech, vaccine and plasma industries. Its features are protected by a portfolio of patents[1-6].

Read More
news image

Accelerating Global Access to Gene Therapies: Case Studies from Lowand Middle-Income Countries

whitePaper | October 18, 2022

This document is published by the World Economic Forum as a contribution to a project, insight area or interaction. The findings, interpretations and conclusions expressed herein are a result

Read More

Spotlight

Orphazyme

Orphazyme is a Danish biotech-company focused on the development of novel therapies for lysosomal storage diseases. Orphazyme was founded in June 2009 by Thomas Kirkegaard Jensen (PhD, CEO), Martin Rahbek Kornum (Patent Attorney, Ch. of Board), Anders Hinsby (Partner, Bankinvest Biomedical Venture) & Marja Jäättelä (Prof., Head of Dep. of Apoptosis) via a pre-seed grant from the Novo Nordisk Foundation.

Events